Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
14 Novembre 2022 - 8:00PM
Nexalin Technology, Inc. (the “Company” or “Nexalin”)
(Nasdaq: NXL; NXLIW) today
announced the publication of a white paper, titled,
“A case report of Nexalin ADI in the treatment of somatic symptoms
of anxiety,” by the Second Xiangya Hospital of Central South
University, China, validating the Company’s tACS device for
the treatment of generalized anxiety disorder. The white paper
details a case study of generalized anxiety disorder treated by the
university with the Nexalin’s tACS device, in which the hospital
reported the disappearance of all somatic anxiety symptoms and
improved quality of sleep. The case study was overseen
by the National Clinical Research Center for Mental Disorders.
The Second Xiangya Hospital of Central South
University provided the following statement: “We are pleased to be
working with Nexalin in bringing this new, effective, safe, and
drug-free therapy to our patients with mental and neurodegenerative
illnesses. We are encouraged by the results of this patient
with generalized anxiety disorder, who received treatment with
the 15 milliamp, Nexalin tACS device. The treatment consisted of 2
treatments per day over 10 days. The patient, a 42 year old female
teacher, suffered repeated physical discomfort for 23 years, as
well as anxiety and sleep disturbance for 6 months. Her
condition was diagnosed as systemic somatic symptoms caused by
severe anxiety. We observed the elimination of all somatic symptoms
caused by excessive anxiety and a meaningful improvement in the
quality of sleep. This case report demonstrated the value and
effectiveness of the Nexalin tACS device in treating insomnia,
anxiety, and somatic symptoms in this patient. Moreover, the effect
was rapid and without any side effects. Importantly, the treatment
effect persisted after 4 months of follow-up. The findings of
this trial considerably expand the possibilities for more effective
therapies for patients with generalized anxiety disorder,
while eliminating the concern associated with the side effects of
psychiatric drugs. As a result, we look forward to conducting a
larger clinical research study.”The Second Xiangya Hospital,
founded in 1958, is an affiliate of Central South University, which
is the largest Class A hospital in Hunan province. According to
Fudan University’s ranking of hospitals in China, the hospital
ranks 13th in comprehensive strength and 15th in specialist areas.
The hospital spans 3,500 beds, 40 clinical departments, 9 medical
laboratories, 127 wards and 4,985
employees. Nexalin’s tACS technology is a safe,
drug-free, non-invasive treatment method, originally cleared to
treat patients with anxiety, depression, and insomnia.
Nexalin has now developed a patented tACS device, which produces a
15 milliamp waveform, designed to penetrate structures deep in the
mid-brain that are associated with a variety of mental health
disorders. It is believed that Nexalin’s 15 milliamp waveform will
correct irregularities in the brain’s neurochemical system. Low
levels of serotonin (5-hydroxytryptamine, 5-HT) in the brain’s
neurochemical system have been associated with various mental
health issues. In 2021, Nexalin’s tACS device was approved by
China’s National Medical Products Administration (NMPA) for
insomnia and depression.Mark White, CEO of Nexalin Technology,
noted, “We are honored to have our neurostimulation technology
featured in a white paper by this prestigious university hospital.
This white paper reinforces the growing body of clinical evidence
supporting the Nexalin 15 milliamp device, which we believe can
have a significant impact on improving mental healthcare outcomes
among patients affected with generalized anxiety disorder. The
adoption of our medical device is poised to enhance mental
healthcare as medical providers learn that our neurostimulation
technology offers a proven alternative to psychiatric drugs.
Nexalin intends to improve the treatment of generalized
anxiety disorder and other neurodegenerative diseases. Nexalin’s
team leads the industry in the clinical research of
neurostimulation for the treatment of mental health diseases. We
intend to bring our expertise to treatment applications, such as
substance use disorder (SUD), Alzheimer’s and chronic
pain. Our mission is to aggressively expand market
awareness of our breakthrough technology around the world.”
About Nexalin Technology,
Inc.Nexalin designs and develops innovative
neurostimulation products to uniquely and effectively help combat
the ongoing global mental health epidemic. All Nexalin’s products
are non-invasive and undetectable to the human body and provide
relief to those afflicted with mental health issues without adverse
side effects. Nexalin utilizes bioelectronic medical technology to
treat mental health issues without the need for drugs or
psychotherapy. Nexalin believes the 15 milliamp medical device can
penetrate structures deep in the mid-brain that are associated with
mental health disorders. Nexalin believes the deeper penetrating
waveform will generate enhanced patient response without any
adverse side effects. The Nexalin tACS device was recently approved
in China by the National Medical Products Administration (NMPA) for
the treatment of insomnia and depression. In September 2018,
Nexalin entered into a series of agreements with Wider Come Limited
(“Wider”), a company formed under the laws of the People’s Republic
of China. Pursuant to this agreement, Nexalin and Wider have agreed
to explore the formation of a joint venture entity to be domiciled
in Hong Kong. This new entity will conduct clinical research and
implement a business distribution plan for the Nexalin device in
the Asia Pacific region. Additional information about the Company
is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTSThis
press release contains statements that constitute "forward-looking
statements," including with respect to the Company’s initial public
offering. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the Company,
including those set forth in the Risk Factors section of the
Company's registration statement and prospectus for the offering
filed with the SEC. Copies are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
Contact:Crescendo Communications,
LLCTel: (212) 671-1020Email: NXL@crescendo-ir.com
Grafico Azioni Nexalin Technologies (NASDAQ:NXL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Nexalin Technologies (NASDAQ:NXL)
Storico
Da Giu 2023 a Giu 2024